Randomized trial shows PTK6 expression predicts worse prognosis in endometrial carcinoma, suggesting its role in treatment strategies.
Background Uterine corpus endometrial carcinoma (UCEC) incidence rises globally, with >50% of advanced/recurrent patients showing poor response to immune checkpoint inhibitors due to inadequate biomarkers. Protein tyrosine kinase 6 (PTK6), aberrantly expressed in malignancies and linked to tumor progression, lacks defined clinical significance in UCEC. Methods Multi-omics analysis utilized UCEC RNA-seq (TCGA/GEO) and proteomics (CPTAC). PTK6 protein interactors from STRING were used for functional enrichment analysis. Tumor microenvironment (TME) was assessed via ESTIMATE (stromal/immune scores), TIMER3 (immune infiltration), and TCIA (immunophenoscore, IPS). Immunohistochemistry (IHC) validation ( n = 200) explored the prognostic value. Results PTK6 was upregulated in UCEC ( p < 0.001) with promoter hypomethylation (median β: 0.32 vs. normal 0.52, p < 0.001), highest in microsatellite instability-high (MSI-H) subtype, and correlated with tumor mutational burden (TMB). High PTK6 expression associated with worse overall survival (OS) in both entire cohort (HR = 2.065, 95% CI 1.060–4.203, p = 0.033) and MSI-H subtype (HR = 8.562, 95% CI 2.226–32.930, p = 0.0018). Exploratory analysis suggested low PTK6-linked reduced progression-free survival in POLE subtype (HR = 10.48, 95% CI 1.063–103.4, p = 0.044; wide CI suggests caution). PTK6-related genes were mainly involved in ERBB signaling, PD-1/PD-L1 immune checkpoint in cancers, and focal adhesion. Upregulated PTK6 was associated with an altered TME (increased neutrophils, decreased CD8 + T cells, reduced IPS; all p < 0.05). IHC confirmed PTK6 overexpression as an independent poor prognostic factor for OS (HR = 5.050, 95% CI 2.136–11.943, p < 0.001), associating with aggressive clinicopathological features (all p < 0.05). Conclusion PTK6 represents a context-dependent prognostic biomarker linked to tumor immune microenvironment remodeling in UCEC, suggesting its potential utility for immunotherapeutic optimization.
No takes yet. Share an insight, caveat, or question.
Ma et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: